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Abstract
Considering the relation between synovial inflammation and
global disease activity in rheumatoid arthritis (RA) and the
distinct but heterogeneous histology of spondyloarthropathy
(SpA) synovitis, the present study analyzed whether
histopathological features of synovium reflect specific
phenotypes and/or global disease activity in SpA. Synovial
biopsies obtained from 99 SpA and 86 RA patients with active
knee synovitis were analyzed for 15 histological and
immunohistochemical markers. Correlations with swollen joint
count, serum C-reactive protein concentrations, and erythrocyte
sedimentation rate were analyzed using classical and
multiparameter statistics. SpA synovitis was characterized by
higher vascularity and infiltration with CD163+ macrophages
and polymorphonuclear leukocytes (PMNs) and by lower values
for lining-layer hyperplasia, lymphoid aggregates, CD1a+ cells,
intracellular citrullinated proteins, and MHC–HC gp39
complexes than RA synovitis. Unsupervised clustering of the
SpA samples based on synovial features identified two separate
clusters that both contained different SpA subtypes but were
significantly differentiated by concentration of C-reactive protein
and erythrocyte sedimentation rate. Global disease activity in
SpA correlated significantly with lining-layer hyperplasia as well
as with inflammatory infiltration with macrophages, especially
the CD163+ subset, and with PMNs. Accordingly, supervised
clustering using these synovial parameters identified a cluster of
20 SpA patients with significantly higher disease activity, and
this finding was confirmed in an independent SpA cohort.
However, multiparameter models based on synovial
histopathology were relatively poor predictors of disease activity
in individual patients. In conclusion, these data indicate that
inflammatory infiltration of the synovium with CD163+
macrophages and PMNs as well as lining-layer hyperplasia
reflect global disease activity in SpA, independently of the SpA
subtype. These data support a prominent role for innate immune
cells in SpA synovitis and warrant further evaluation of synovial
histopathology as a surrogate marker in early-phase therapeutic
trials in SpA.
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Introduction
Whereas classical analysis of synovial tissue in chronic
inflammatory arthritis suggested that synovitis is a nonspe-
cific phenomenon, a number of studies using new molecu-
lar tools and synovial biopsies obtained during active
disease indicated clear histopathological differences
between spondyloarthropathy (SpA) and rheumatoid arthri-
tis (RA), which are the two most frequent forms of chronic
autoimmune arthritis [1-4]. These differences were
explored as a diagnostic tool in undifferentiated arthritis
[5,6], and highly disease-specific markers as well as less
pronounced synovial features turned out to be useful in
multiparameter classification models [7,8]. Since some of
these features are pathophysiologically related to specificR359
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that histopathological characteristics of inflamed synovium
directly reflect the disease process.
In RA, it has been shown that synovial features may help to
distinguish different subgroups corresponding to distinct
pathogenetic mechanisms and clinical phenotypes. Indeed,
three main histological types of synovitis can be distin-
guished in RA: one type characterized by follicular organi-
zation with high numbers of B cells and plasma cells,
another type with diffuse infiltration by essentially T lym-
phocytes and macrophages, and a third, granulomatous
type, which is less frequent [9]. The different histological
types are stable over time within one individual, are linked
with different cellular and molecular disease pathways, as
evidenced, for example, by abundant IL-10 in the follicular
type, and are related to phenotypic differences such as
seronegativity in the diffuse type and extra-articular mani-
festations in the granulomatous type [10,11]. Besides dis-
tinguishing subtypes within one disease, some of these
features may also reflect global disease activity and thus be
valuable candidates for evaluation as surrogate markers in
trials of new, targeted therapies in autoimmune arthritis.
Synovial macrophages have been shown to be related to
scores for local disease activity as well as to articular dam-
age in RA [12,13]. Sublining macrophages, but also T cells
and plasma cells, were increased in clinically involved ver-
sus clinically uninvolved knee joints [14], while sublining
macrophages were also increased in joints in active RA
compared with joints in end-stage disease [15]. Taken
together, these various findings strongly suggest that the
number of sublining macrophages is a good reflection of
active disease processes in RA. This interpretation was fur-
ther validated by demonstrating that synovial sublining
macrophages can be used as surrogate marker for global
disease activity in clinical trials evaluating antirheumatic
therapy in RA [16].
In contrast with the situation with RA, these issues have not
yet been fully assessed in SpA. We have previously dem-
onstrated a correlation between synovial histology and
local disease activity in SpA [1] and the absence of mani-
fest differences in synovial histopathology between psori-
atic arthritis (PsA) and other SpA subtypes. Considering
the data in RA synovitis, the increase of specific macro-
phage subsets and polymorphonuclear leukocytes (PMNs)
in SpA synovium compared with RA [2], and the strong and
rapid reduction of synovial macrophages, T lymphocytes,
and PMNs during treatment with anti-tumor-necrosis-factor
(TNF)-α in SpA [17,18], the objective of the present study
was to analyze in more detail whether histopathological fea-
tures of the synovial membrane reflect specific phenotypes
and/or global disease activity in SpA.
Materials and methods
Patients and samples
The study included 99 SpA patients fulfilling the criteria of
the European Spondyloarthropathy Study Group [19]. One
cohort consisted of 82 patients, including 19 with ankylos-
ing spondylitis (AS), 33 with PsA, 24 with undifferentiated
SpA (USpA), 4 with SpA associated with inflammatory
bowel disease, and 2 with reactive arthritis. Since we had
previously found no major differences between these SpA
subgroups for the synovial histopathology markers used in
the present study, we considered them collectively as hav-
ing SpA (unpublished data). All patients had active disease
at the time of inclusion, as evidenced by a mean swollen
joint count (SJC) of 3.5 ± 4.1 (mean ± standard deviation),
a mean serum C-reactive protein (CRP) concentration of
33 ± 45 mg/L, and a mean erythrocyte sedimentation rate
(ESR) of 28 ± 24 mm/hour. The mean duration of disease
was 5.5 ± 5.4 years, and 23 of the 82 patients were being
treated with a disease-modifying antirheumatic drug
(DMARD); none of the patients were being treated with
corticosteroids. All patients had at least one swollen knee
joint, from which synovial biopsies were sampled by needle
arthroscopy.
As an independent validation group, a second cohort of 17
SpA patients (4 with AS, 5 with PsA, 8 with USpA) fulfilling
the same inclusion criteria was included in the study. This
group had a mean SJC of 5.5 ± 5.4, a mean serum CRP of
38 ± 48 mg/L, and a mean ESR of 31 ± 27 mm/hour. None
of these patients was receiving DMARDs or corticoster-
oids. The mean duration of disease in this group was 10.8
± 10.2 years.
For the control group, we included 86 patients fulfilling the
American College of Rheumatology criteria for RA [20]. As
for the SpA cohort, all RA patients had at least one swollen
knee joint and had active disease, with a mean SJC of 9.2
± 6.6, a mean serum CRP of 58 ± 67 mg/L, and a mean
ESR of 41 ± 27 mm/hour. The mean duration of disease
was 6.0 ± 7.5 years. Fourteen patients were receiving
DMARDs, 5 patients were receiving corticosteroids, and
21 patients were receiving both.
In all the patients, synovial tissue biopsies (16 from each
person) were obtained by needle arthroscopy of a clinically
involved knee joint, as described previously [21]. All
patients gave their written, informed consent before inclu-
sion in the study, which was approved by the Ethics Com-
mittee of the Ghent University Hospital.
Synovial histopathology
Synovial biopsies were fixed, stained, and scored as
described previously [1-4]. Briefly, eight paraffin-embed-
ded biopsies were stained with H&E for histological analy-
sis, including mean thickness of the synovial lining-layer,
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layer, and the presence of lymphoid aggregates, plasma
cells, and PMNs. A separate analysis in 93 samples
showed that the evaluation of the number of blood vessels
and the number of plasma cells on H&E staining correlated
well with staining for, respectively, the endothelial marker
CD146 (r = 0.436; P < 0.0001) and the plasma cell marker
CD138 (r = 0.621; P < 0.0001). The remaining eight biop-
sies were embedded in tissue-freezing medium and used
for immunohistochemistry with the following antibodies:
anti-CD1a (interdigitating dendritic cells, mouse, mono-
clonal; Dako, Glostrup, Denmark), anti-CD3 (T cells,
mouse, monoclonal; Dako), anti-CD20 (B cells, mouse,
monoclonal; Dako), anti-CD68 (monocytes and macro-
phages, mouse, monoclonal, clone EBM11; Dako), anti-
CD163 (scavenger receptor expressed on mature tissue
macrophages, mouse, monoclonal, clone Ber-MAC3;
Dako), anti-L-citrulline (citrullinated peptides, rabbit, poly-
clonal; Biogenesis, Poole, UK), and mAb 12A (detecting
MHC class II–HC gp39 peptide complexes, mouse, mono-
clonal; NV Organon, Oss, Netherlands). Parallel sections
were stained with irrelevant origin-, isotype-, and concen-
tration-matched antibody as negative control. Stained sec-
tions were coded and analyzed by two independent
observers, who were blinded to the diagnosis and clinical
data. Due to the low number of positive cells in each sam-
ple for anticitrulline, anti-CD1a, and mAb 12A staining,
these parameters as well as lymphoid aggregates were
scored as present or absent. For all other parameters, the
analysis included all areas of the biopsies, and a global
score was given for each parameter, using a semiquantita-
tive 4-point scale: 0 represented the lowest and 3 the high-
est level of expression [1-4]. As some histological markers
are more abundant than others, the scoring system was
calibrated for each marker separately by examining a repre-
sentative number of samples. In case of discordant scores
between the two observers, the mean of the two scores
was used. Since anti-CD68 and anti-CD163 staining,
which recognizes a particular subset of the CD68+ macro-
phages [2], was observed in both the synovial lining layer
and the synovial sublining layer, these markers were scored
separately in the two compartments. An overview of the 15
synovial parameters is given in Table 1.
Statistics
The histopathological features of the synovial membrane in
SpA and RA were compared using the Mann–Whitney U
test for semiquantitative parameters and the χ2 test for
dichotomous parameters. Histopathological subgroups
were identified by clustering analysis (within-group average
linkage with Pearson correlation) using SPSS version 12.0
software (SSPS Inc, Chicago, IL, USA). Correlations
Table 1
Histopathological features and scoring systems used to evaluate synovial inflammation
Feature Scoring system
Assessed by histology
Lining-layer hyperplasia Semiquantitative
Degree of vascularity Semiquantitative
Inflammatory infiltration Semiquantitative
Lymphoid aggregates Present or absent
Plasma cells Semiquantitative
Polymorphonuclear leukocytes Semiquantitative
Assessed by immunohistochemistry
CD1a Present or absent
CD3 Semiquantitative
CD20 Semiquantitative
CD68 lining layer Semiquantitative
CD68 sublining layer Semiquantitative
CD163 lining layer Semiquantitative
CD163 sublining layer Semiquantitative
Intracellular citrullinated peptides Present or absent
MHC class II–HC gp39 peptide complex, recognized by mAb 12A Present or absent
Arthritis Research & Therapy    Vol 7 No 2    Baeten et al.
R362between semiquantitative histological parameters and clin-
ical disease activity markers (SJC, CRP, ESR) were
calculated using the Spearman ρ test. For dichotomous
histological markers, the clincal disease activity parameters
of the positive and negative groups were compared using
an unpaired Student's t-test. A P value of less than 0.05
was considered statistically significant.
The relation between the 15 histological parameters and
the 3 clinical parameters was also analyzed by SAM (signif-
icance analysis of microarray) software, a statistical analy-
sis model that was specifically developed for
multiparameter datasets [22] (see also http://www-
stat.stanford.edu/~tibs/SAM/index.html). Measuring the
relation between changes in the input parameter (which are
here the 15 histological features) and changes in the
response variable (SJC, CRP, and ESR), the software
assigns a score (expressed as a value d) reflecting the
strength of the observed differences. To assess the signifi-
cance of this relationship, a value q is calculated by permu-
tations of the measurements to estimate the percentage of
parameters identified by chance, the false discovery rate
(FDR). Using SJC, CRP, or ESR as quantitative response
parameters, d>2 (indicating that the strength of the associ-
ation between the histological input parameter and the dis-
ease activity outcome parameter was at least twice the
expected value) and q<0.10 (corresponding to an α error
of less than 10% in classical statistics or, in other words,
indicating that the observed associations had a 90%
chance of being real) were considered significant.
Finally, histological parameters that not only are correlated
with disease activity but also contribute significantly to the
prediction of the disease activity in individual samples were
identified by PAM (predictive analysis of microarray) soft-
ware [23]. Whereas SAM is intended to identify significant
differences between groups of samples, PAM is intended
to identify those parameters that are most useful in predict-
ing the outcome (in this case, disease activity) in individual
samples and to combine those parameters in an optimal
multiparameter algorithm to classify single samples or
patients.
Results
Comparative histopathology of SpA and RA
The scores for the histopathological features of the synovial
membrane in SpA and RA are given in Table 2. There was
significantly higher vascularity (P = 0.013), lining CD163
(P < 0.001), and sublining CD163 (P = 0.003) in SpA than
in RA. There was also a trend towards an increase of PMNs
Table 2
Synovial histopathology in spondyloarthropathy and rheumatoid arthritis
Feature Spondyloarthropathya Rheumatoid arthritisa
Lining-layer thickness 1 (1–3)* 1.5 (1–3)*
Vascularity 2 (0–3)* 1.5 (0–3)*
Inflammatory infiltration 1.5 (0–3) 2 (0–3)
Plasma cells 0 (0–3) 0 (0–3)
Polymorphonuclear leukocytes 0 (0–3) 0 (0–2.5)
CD3 1.5 (0–3) 2 (0–3)
CD20 1 (0–3) 1.5 (0–3)
CD68 in lining layer 1 (0–3) 1 (0–3)
CD68 in sublining layer 0.5 (0–3) 1 (0–3)
CD163 in lining layer 1.5 (0–3)* 0.5 (0–3)*
CD163 in sublining layer 1.5 (0–3)* 0.5 (0–3)*
Lymphoid aggregates 17/65* 32/54*
CD1a 18/64* 36/50*
Anticitrulline staining 0/82* 27/59*
mAb 12A staining 1/81* 28/58*
aResults are expressed as median (range) for semiquantitative scores and present/absent for dichotomous parameters. As indictated in Materials 
and methods, stained sections were scored by two blinded observers using a semiquantitative scale from 0 (lowest expression) to 3 (highest level 
of expression). This scale was calibrated for each marker separately and the mean of the two scores was used.
*P < 0.05.
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lower score in SpA versus RA for lining-layer thickness (P
= 0.032), CD1a (P = 0.009), lymphoid aggregates (P =
0.029), anticitrulline staining (P < 0.001), and mAb 12A
staining (P < 0.001). In contrast with CD163, no differ-
ences were found for the pan-macrophage marker CD68 in
the lining or sublining layer. The number of plasma cells,
which were found in 32 of the 82 SpA samples and 40 of
the 86 RA samples, was also not different between the two
diseases. Although the mean age of the patients was
higher in the RA cohort (56.2 ± 14.9 years) than in the SpA
cohort (42.6 ± 13.3 years), none of the differentiating
parameters was related to age, excluding the possibility
that the difference in age could have induced a systematic
bias in the comparison. These findings, which are illus-
trated in Fig. 1, are in agreement with previous observa-
tions [1-4] and indicate that the patient cohorts used in the
present study are representative of the full-blown SpA or
RA synovial histopathology.
Histopathological heterogeneity within SpA
With the exception of anticitrulline and mAb 12A staining,
which were found almost exclusively in RA, all investigated
histopathological parameters showed a wide range of
scores within the SpA group, reflecting wide interindividual
variability. Therefore, we next tried to identify specific SpA
subgroups by combining the different histological features
in a multiparameter model using clustering analysis. Unsu-
pervised analysis yielded two main clusters within SpA,
consisting of 39 and 43 samples (Fig. 2). Although there
were slightly more AS samples in cluster 2, the different
SpA subtypes were found both in cluster 1 (4 AS, 14
USpA, 16 PsA, 4 inflammatory bowel disease, 1 reactive
arthritis) and in cluster 2 (15 AS, 10 USpA, 17 PsA, 1 reac-
tive arthritis), confirming that synovial histopathology is not
basically different between SpA subtypes. The mean dura-
tion of disease (5.4 ± 5.0 versus 5.7 ± 5.9 years, respec-
tively), the use of DMARDs (in 10 of 39 versus 13 of 43),
and the mean SJC (3.1 ± 3.3 versus 3.8 ± 4.7, respec-
tively) were not different between cluster 1 and cluster 2. In
contrast, both serum CRP concentrations (14 ± 12 mg/L
versus 51 ± 56 mg/L; P < 0.001) and ESR (19 ± 17 mm/
hour versus 35 ± 28 mm/hour; P = 0.003) were signifi-
cantly lower in cluster 1 than in cluster 2 (Fig. 3), indicating
that this unsupervised classification based on the synovial
histopathology reflects the global disease activity. In con-
trast, a similar analysis of the RA cohort yielded five sepa-
rate clusters, without significant differences in SJC, serum
CRP concentrations, or ESR between the clusters (data
not shown).
When the two clusters of the SpA cohort were compared,
the cluster with higher CRP and ESR was found to show a
significant increase of the following histological parame-
ters: vascularity (P = 0.001), inflammatory infiltration (P <
0.001), lymphoid aggregates (P = 0.027), plasma cells (P
= 0.001), PMNs (P < 0.001), CD3+ lymphocytes (P <
0.001), and CD20+ lymphocytes (P = 0.007).
Relation between synovial histopathology and disease 
activity in SpA
Since these data suggest that synovial histopathology
reflects global disease activity in SpA, we further analyzed
the correlation of individual histological parameters with
SJC, CRP, and ESR in the SpA cohort. In order to minimize
the risk of false-positive results, only the parameters identi-
fied by both classical statistics and SAM analysis were con-
sidered as significant. As shown in more detail in Table 3
(top), lining-layer thickness, sublining CD68, and sublining
CD163 were weakly but significantly correlated with the
Figure 1
Distinct synovial features in spondyloarthropathy (SpA) and rheumatoid arthritis (RA)
arthritis (RA). Vascularity, CD163+ macrophages, and polymorphonu-
clear leukocytes (PMNs) were significantly increased in SpA, whereas 
lining-layer hyperplasia, lymphoid aggregates, CD1a+ dendritic cells, 
intracellular citrullinated proteins (detected by anticitrulline staining), 
and MHC–HC gp39 complexes (detected by staining with monoclonal 
antibody (mAb) 12A) were higher in RA.
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with inflammatory infiltration, PMNs, and sublining CD163.
Finally, ESR correlated with lining-layer thickness, inflam-
matory infiltration, PMNs, and sublining CD163. Thus, it
appears that global disease activity in SpA is essentially
associated with inflammatory infiltration with macrophages
– especially the CD163+ subset – and PMNs as well as
with lining-layer hyperplasia. Although some of the correla-
tions were relatively weak, the number of CD163+ macro-
phages in the sublining appeared to be consistently
correlated with the three different measures of disease
activity, whereas inflammatory infiltration and PMNs
showed a stronger correlation with the systemic inflamma-
tory parameters.
For comparison, we performed the same analysis in the RA
control group. As shown in more detail in Table 3 (bottom),
no histological parameters were significantly correlated
with the SJC. Serum CRP concentrations were significantly
associated with CD3 and mAb 12A staining. ESR was
correlated with CD3 as well as with sublining CD68 and
anticitrulline staining. Globally, the correlations were
weaker and less consistent in RA than in SpA.
Supervised clustering in relation with disease activity in 
SpA
On the basis of the previous findings, we redefined two
separate clusters within the SpA cohort based not on all
synovial features, but on the five synovial characteristics
that were significantly associated with disease activity: lin-
ing-layer hyperplasia, inflammatory infiltration, PMNs, sub-
lining CD68, and sublining CD163. Cluster 1 (n = 62) was
characterized by significantly lower SJC (3.0 ± 3.2 versus
5.2 ± 5.8; P = 0.037), serum CRP concentrations (23 ± 32
mg/L versus 66 ± 63 mg/L; P < 0.001), and ESR (21 ± 19
mm/hour versus 48 ± 28 mm/hour; P < 0.001) than cluster
2 (n = 20) (Fig. 4a). Again, there were no significant differ-
ences between the two clusters with regard to the SpA
subtypes (12 AS, 21 USpA, 24 PsA, 3 inflammatory bowel
disease, and 2 reactive arthritis in cluster 1 versus 7 AS, 3
USpA, 9 PsA, and 1 inflammatory bowel disease in cluster
2), indicating the absence of a relation between histopa-
thology and disease phenotypes. Moreover, there was no
difference in DMARD treatment (5 of 20 versus 18 of 62)
or disease duration (4.0 ± 5.3 versus 5.8 ± 5.5 years)
between the two clusters. In other words, the five
previously defined histological parameters were able to
identify a subgroup of SpA patients with high disease activ-
ity independently of the SpA subtype, treatment, and dis-
ease duration, thereby confirming that synovial
histopathology reflects not only local inflammation but also
global disease activity in SpA.
In contrast, a similar analysis of the RA cohort using CD3,
sublining CD68, anticitrulline, and mAb 12A as input
parameters yielded two clusters (with respectively n = 41
and n = 45 samples) that were not different with regard to
SJC (9.1 ± 6.3 versus 9.2 ± 7.0), serum CRP concentra-
tions (52 ± 43 mg/L versus 64 ± 82 mg/L), or ESR (42 ±
27 mm/hour versus 40 ± 28 mm/hour).
Confirmation of the supervised clustering analysis on an 
independent SpA cohort
To confirm these findings, we applied the same supervised
clustering analysis based on the five previously defined his-
Figure 2
Unsupervised clustering analysis using synovial histopathological param ter  i entified two main cl ters within the spondyloarthropathy cohort (n = 82)
parameters identified two main clusters within the spondyloarthropathy 
cohort (n = 82). The dendrogram represents the 82 spondylarthropathy 
cases on the y-axis, classified according to their similarity for the histo-
logical parameters. The degree of similarity is represented as rescaled 
distance on the x-axis: when two samples are closely similar the dis-
tance will be small, whereas a rescaled distance of 25 represents a 
high degree of histological difference.
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patients, none of whom were being treated with DMARDs.
Two clusters were identified: cluster 1, consisting of 7
patients (1 with AS, 2 with PsA, 4 with USpA) and cluster
2, consisting of 10 patients (3 with AS, 3 with PsA, 4 with
USpA). The mean disease duration in the two clusters was
similar (10.7 ± 6.9 versus 10.8 ± 12.4 years, respectively).
However, the two clusters were again significantly different
with regard to SJC (9.3 ± 6.6 versus 2.9 ± 2.3; P = 0.012),
serum CRP concentrations (75 ± 55 versus 13 ± 18 mg/
L; P = 0.004), and ESR (55 ± 18 versus 15 ± 20 mm/hour;
P = 0.001) (Fig. 4b). Thus, this analysis in an independent
validation cohort confirms that well-defined synovial his-
topathological features in SpA reflect global disease
activity independently of SpA subtype, disease duration,
and treatment.
Prediction of global disease activity in individual SpA 
samples
Since the previous data provided evidence that lining-layer
hyperplasia and infiltration with PMNs and macrophage
subsets are directly related to the global disease activity in
SpA, we next investigated whether synovial histopathology
could be a valuable surrogate marker for the prediction of
disease activity in individual patients rather than in a patient
cohort. Using PAM to classify the 82 SpA patients into
tertiles (low, middle, and high disease activity) for respec-
tively SJC, CRP, and ESR, the same histological parame-
ters were identified as having the largest contribution to the
predictive algorithms: inflammatory infiltration, sublining
CD163, PMNs, sublining CD68, and lining CD68. How-
ever, the positive predictive value of these models was rel-
atively poor, as shown by the correct classification of only
51%, 55%, and 49% of the samples for SJC, CRP, and
ESR, respectively, compared with an a priori chance of
33%. Similarly, PAM analysis using histopathological
parameters was not able to make a good prediction of sam-
ples belonging to the highest quartile for disease activity
(data not shown). These data indicate that although the
previously identified histological parameters are related to
disease activity, the wide interindividual variability does not
allow a robust prediction in single patients.
Discussion
It has previously been shown that the synovial histopathol-
ogy in inflammatory arthritis is dependent on both the dis-
ease background and the local disease activity [1,2,12,15].
When focusing on SpA patients with active synovitis of the
investigated joint, however, we still observe a large hetero-
geneity in synovial features. In an attempt to translate these
histological findings into clinically relevant patterns, we
assessed whether this heterogeneity was related to the
fact that SpA consists of different subtypes with distinct
phenotypes. Confirming a recent report in which we found
no significant differences between PsA on the one hand
and AS and USpA on the other hand (unpublished data),
both unsupervised and supervised clustering analysis of
the present data indicated that the synovial heterogeneity
is not basically associated with specific SpA phenotypes.
In contrast, the present study reveals that this heterogene-
ity directly reflects the global disease activity in SpA. Con-
sidering that there are no validated global disease
parameters for SpA as a whole, the present study used
SJC, serum CRP concentrations, and ESR as clinical out-
comes. Although these parameters are not elevated in all
patients with active SpA, several studies have shown that
peripheral arthritis as well as systemic inflammatory param-
Figure 3
Unsupervised clustering analysis using synovial histopathological parameters identified two main clusters within the spondyloarthropathy (SpA) cohort (n = 82)
cohort (n = 82). Whereas there were no differences for the swollen jount count between the two clusters, cluster 2 was characterized by signifi-
cantly higher serum C-reactive protein concentrations (mg/L) and erythrocyte sedimentation rate (mm/hour). Data are represented as box–whisker 
plots, with median, 25th to 75th percentile, and 5th to 95th percentile. Comparisons were performed with the Mann–Whitney U test.
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context, the present finding that local synovial features are
correlated with systemic inflammatory parameters such as
CRP and ESR strengthens the concept that peripheral
synovitis, although not present in all SpA patients, contrib-
utes significantly to disease severity.
Further analysis revealed that not all synovial features were
correlated with disease activity. Both classical statistics
and SAM analysis demonstrated a correlation with lining-
layer hyperplasia and, more consistently, inflammatory infil-
tration by CD163+ macrophages and PMNs. We previ-
ously shown that these CD163+ macrophages, but not the
overall number of CD68+ macrophages, are increased in
SpA synovitis and play a specific role in the disease patho-
genesis [2,26]. In contrast, neither synovial hypervascular-
ity, which is clearly increased in SpA versus RA and
contributes to diagnostic classification [1,7], nor lym-
phocyte-related characteristics (CD3, CD20, plasma cells,
lymphoid aggregates) were associated with SJC, CRP, or
ESR. This was further confirmed by a supervised clustering
analysis that could even better identify a high-disease-activ-
ity group on the basis of only five synovial features, both in
the first SpA cohort that was used to identify these features
and, most importantly, in a completely independent SpA
cohort. Both the previous reports and the present study
pointed towards the increased presence of CD163+ mac-
rophages and PMNs in SpA versus RA synovitis [2,27].
Moreover, in the RA control group the global disease activ-
ity parameters correlated not with these features, but with
lymphocyte-related characteristics such as CD3 and puta-
tive B- and T-cell autoantigens in RA (intracellular citrulli-
nated proteins and MHC–HC gp39 complexes) [3,4].
Although certainly not excluding a secondary effector func-
tion for lymphocytes in SpA or for macrophages in RA syn-
ovitis, these findings point towards distinct pathogenetic
Figure 4
Supervised clustering analysis using the synovial histopathological parameters that were significantly associated with disease activity in spondyloar-thropathy (SpA) (lining-layer hyperplasia, inflammatory infiltration, polymorphonuclear cells, sublini g CD68, nd sublining CD163)
thropathy (SpA) (lining-layer hyperplasia, inflammatory infiltration, polymorphonuclear cells, sublining CD68, and sublining CD163). (a) Analysis in 
the cohort of 82 patients originally used to identify the histopathological parameters identified a cluster (cluster 2, n = 20 samples) which was char-
acterized by significantly higher swollen joint count, serum C-reactive protein concentrations (mg/L), and erythrocyte sedimentation rate (mm/hour). 
(b)A similar analysis in an independent cohort of 17 patients confirmed these results by identifying a cluster of 7 patients (cluster 2) that was simi-
larly characterized by significantly higher swollen joint count, serum C-reactive protein concentrations (mg/L), and erythrocyte sedimentation rate 
(mm/hour). Data are represented as box–whisker plots, with median, 25th to 75th percentile, and 5th to 95th percentile. Comparisons were per-
formed with the Mann–Whitney U test.
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R367mechanisms in the two diseases and fit well with the
hypothesis that SpA synovitis is primarly driven by innate
immune cells with secondary alterations in lymphocyte acti-
vation and functions [28].
Independently of these pathogenetic considerations, the
present data also raise the question of the value of synovial
histopathology as a biomarker in SpA. Despite the fact that
lining-layer hyperplasia and inflammatory infiltration with
CD163+ macrophages and PMNs reflected the global
Table 3
Association of single histopathological features with three measures of disease activity in spondyloarthropathy (top) and in 
rheumatoid arthritis (bottom)
Histological feature SJC CRP ESR
Correlationa SAM Correlationa SAM Correlationa SAM
In spondylarthropathy
Lining-layer thickness 0.220 2.16 0.242 NS 0.240 2.30
Vascularity NS NS NS NS NS NS
Inflammatory infiltration NS NS 0.472 2.60 0.336 2.34
Plasma cells NS NS NS NS NS NS
PMNs NS NS 0.393 2.15 0.280 2.58
CD3 NS NS 0.236 NS NS NS
CD20 NS NS NS NS NS NS
Lining CD68 NS NS -0.510 NS -0.372 NS
Sublining CD68 0.278 3.14 NS NS NS NS
Lining CD163 NS NS NS NS NS NS
Sublining CD163 0.281 2.14 0.249 2.06 0.299 3.18
Lymphoid aggregates NS 2.23 NS NS NS NS
CD1a NS NS NS NS NS NS
Anticitrulline staining NS NS NS NS NS NS
mAb 12A staining NS NS NS NS NS NS
In rheumatoid arthritis
Lining-layer thickness 0.222 NS NS NS NS NS
Vascularity NS NS NS NS -0.235 NS
Inflammatory infiltration NS NS NS NS NS NS
Plasma cells NS NS NS NS 0.212 NS
PMNs -0.255 NS NS NS NS NS
CD3 NS NS 0.297 2.02 0.334 2.49
CD20 NS NS NS NS NS NS
Lining CD68 NS NS -0.227 NS NS NS
Sublining CD68 NS NS NS NS 0.304 2.31
Lining CD163 NS NS NS NS NS NS
Sublining CD163 NS NS NS NS NS NS
Lymphoid aggregates NS NS NS NS NS NS
CD1a NS NS NS NS NS NS
Anticitrulline staining NS NS NS NS P = 0.004 2.84
mAb 12A NS NS P = 0.035 2.00 NS NS
Only significant associations are shown. aCorrelations were calculated either by classicial statistics (results are expressed as correlation 
coefficient; for dichotomous parameters differences between the positive and negative group are expressed as P on Student's unpaired t-test) or 
by SAM (significance analysis of microarray) (for which results are expressed as d values). CRP, serum C-reactive protein; ESR, erythrocyte 
sedimentation rate; NS, not significant; PMNs, polymorphonuclear leukocytes; SJC, swollen joint count.
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R368disease activity when cohorts of patients were analyzed,
multiparameter models based on synovial histopathology
turned out to be relatively poor predictors of disease sever-
ity in individual patients. This finding is not totally unex-
pected in view of the wide variability of individual values for
both histology and disease activity and the broad overlap
between different clusters in the previous analyses.
Several factors could play a role in this wide individual var-
iability. Firstly, treatment with DMARDs might be a
confounding factor. However, the facts that most SpA
patients of the first cohort had been given no treatment at
all or were being treated exclusively with nonsteroidal
antirheumatic drugs, that the clustering analysis was not
influenced by treatment, and that the clustering was con-
firmed in an independent cohort without DMARD treatment
are in accord with previous data showing that DMARDs did
not bias the synovial histopathology in patients with persist-
ent, refractory peripheral synovitis (unpublished data).
Moreover, even after exclusion of the DMARD-treated
patients, the prediction models performed poorly (data not
shown). Secondly, the present study used a semiquanti-
tatve scoring system for the histopathology, whereas the
previously mentioned RA studies used digital image analy-
sis [16]. Whereas semiquantitative scoring has been
shown in multiple studies to be robust and reproducible, it
is less sensitive to change than digital image analysis and
might thus underestimate small variations [29]. Thirdly,
recent data obtained with microarrays indicated clearly that
setting up profiles using multiple parameters can compen-
sate for the relative lack of precision and the variability of
individual parameters [30]. As we have already demon-
strated the added value of combining different histopatho-
logical features in multiparameter models for diagnostic
classification of inflammatory arthritis [7,8], the same might
apply to the use of synovial histology as a surrogate marker
for global disease activity.
In this context, early–phase, randomized clinical trials in
SpA might be of particular interest for the use of synovial
histopathology as a biomarker. With the availibility of pow-
erful new treatments such as TNF-α blockers it becomes
increasingly important to obtain as much paraclinical and
biological information as possible in small patient cohorts
early in the clinical development of new drugs. Moreover, in
such trials, the emphasis is on groups with uniform treat-
ment schedules rather than on individual patients, and dif-
ferent biological measurements (such as histology, mRNA
expression levels, serum protein concentrations) can be
combined in multiparameter algorithms, thus overcoming
the previously mentioned caveats. In RA, it has recently
been demonstrated that the number of sublining CD68+
macrophages is a sensitive surrogate marker for response
to therapy [16], even if this feature was only found to corre-
late with ESR in RA in the present cross-sectional study
and was clearly less robust than the previously discussed
SpA parameters. Since the correlations between global
disease activity and synovial histopathology of a single joint
were consistently stronger in SpA than in RA and since pre-
vious studies showed a histopathological response to tar-
geted therapies in SpA and more specifically a decrease of
macrophage subsets and PMNs [17,18,31-33], the data
presented here warrant further prospective and longitudi-
nal analysis of synovial histopathology as a surrogate
marker in the evaluation of new, targeted therapies for SpA.
Conclusion
The data presented indicate that inflammatory infiltration of
the synovium with CD163+ macrophages and PMNs as
well as lining-layer hyperplasia reflect global disease activ-
ity in SpA, independently of the SpA subtype. These data
support a prominent role for innate immune cells in SpA
synovitis and warrant further evaluation of synovial histopa-
thology as a surrogate marker in early-phase therapeutic tri-
als in SpA.
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